Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00403286 · ClinicalTrials.gov registry record · Phase 2
A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease
A Phase 2 study, sponsored by Dey.
- Completed
- Registry status
- Phase 2
- Development phase
- 457
- Enrollment target
NCT00403286 is a Phase 2 study that has completed, run by Dey. The registered enrollment target is 457 participants.
The verdict
NCT00403286, a Phase 2 study, has completed, sponsored by Dey.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 457 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the appropriate dose of fluticasone propionate/formoterol fumarate that is closest to Advair Diskus (fluticasone propionate/salmeterol xinafoate using pulmonary function, safety, and levels of study drug in blood plasma in patients with chronic obstructive pulmonary disease.
Interventions
- DRUG Fluticasone Propionate
- DRUG Fluticasone Propionate/Formoterol Fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 457 participants |
| Start Date | 2006-11 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00403286
The ClinicalTrials.gov registry entry for NCT00403286 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 457 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dey, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fluticasone Propionate is the first listed.
NCT00403286 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00403286 about?
NCT00403286 is a clinical study titled "A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease". The purpose of the study is to determine the appropriate dose of fluticasone propionate/formoterol fumarate that is closest to Advair Diskus (fluticasone propionate/salmeterol xinafoate using pulmonary function, safety, and levels of study drug in blood plasma in patients with chronic obstructive pu...
What is the current status of trial NCT00403286?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 457 participants. The study started on 2006-11. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00403286?
The interventions under investigation include: Fluticasone Propionate (DRUG), Fluticasone Propionate/Formoterol Fumarate (DRUG).
Who is sponsoring clinical trial NCT00403286?
This trial is sponsored by Dey, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.